A Biotech Company's Aggressive Move Backfires
96722
The suspension of Chiron's flu vaccine has not only cost it three-quarters in expected profits, but also some credibility.
748007
The company is fumbling in its attempts to move to a new business model.
673670
Bristol-Myers Squibb struggles to keep growing amid patent expirations.
475502
The drug company posts a wider Q3 loss than a year ago.
100034
In a bit of hockey lingo borrowed by the biotech industry, Sonus Pharmaceuticals just gave itself more &quot;shots on goal.&quot;.
697697
A takeover attempt follows management shakeups at the biopharmaceutical firm.
491379
The company has posted impressive growth, but the industry is struggling.
610181
Stock market investors are infamous for their laser focus on immediate results when they put a price on risk and potential reward every day. Unless, of course, they're investing in biotech stocks.
301149
Cambridge Antibody Technology&#39;s (Nasdaq: CATG) legal victory over Abbott Laboratories (NYSE: ABT) shows that a biotech David can triumph over a pharmaceutical Goliath.
226441
Biotechnology companies are betting that pairing old drugs can be a better business than inventing new ones from scratch.
731230
The biotech mines extra value from its compound library.
172265
Charly Travers offers advice on withstanding the volatility of the biotech sector.
104872
When Genzyme Inc. breaks down its revenue this year, there's a big hole: treatment of cancer.
665690
The developing biopharmaceutical company announces a share offering.
65620
Vertex Pharmaceuticals is losing money. But it has at least one drug that makes the future look brighter.
643031
Management is trying to turn things around, but the company's paying for past mistakes.
760357
Biotech funds differ in their make-up, performance, and promise.